D. Henne-Bruns, I. Vogel, J. Luttges, et al., “Ductal Adenocarcinoma of the Pancreas Head: Survival after Regional versus Extended Lymphadenectomy,” Hepatogastroenterology, Vol. 45, No. 21, 1998, pp. 855-866.
 C. D. Johnson, G. Schwall, J. Flechtenmacher and M. Trede, “Resection for Adenocarcinoma of the Body and Tail of the Pancreas,” British Journal of Surgery, Vol. 80, No. 9, 1993, pp. 1177-1179. http://dx.doi.org/10.1002/bjs.1800800937
 M. Mukaiya, K. Hirata, T. Satoh, et al., “Lack of Survival Benefit of Extended Lymph Node Dissection for Ductal Adenocarcinoma of the Head of the Pancreas: Retrospective Multi-Institutional Analysis in Japan,” World Journal of Surgery, Vol. 22, No. 3, 1998, pp. 248-252. http://dx.doi.org/10.1007/ s002689900378
 S. P. Cleary, R. Gryfe, M. Guindi, et al., “Prognostic Factors in Resected Pancreatic Adenocarcinoma: Analysis of Actual 5-Year Survivors,” Journal of the American College of Surgeons, Vol. 198, No. 5, 2004, pp. 722-731. http://dx.doi.org/10.1016/j.jamcollsurg.2004.01.008
 J. Hernandez, J. Mullinax, W. Clark, et al., “Survival after Pancreaticoduodenectomy Is Not Improved by Extending Resections to Achieve Negative Margins,” Annals of Surgery, Vol. 250, No. 1, 2009, pp. 76-80. http://dx.doi.org/10.1097/01.sla.0000259391.84304.2b
 C. P. Raut, J. F. Tseng, C. C. Sun, et al., “Impact of Resection Status on Pattern of Failure and Survival after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma,” Annals of Surgery, Vol. 246, No. 1, 2007, pp. 52-60. http://dx.doi.org/10.1097/01.sla.0000259391.84304.2b
 P. Toomey, J. Hernandez, C. Morton, et al., “Resection of Portovenous Structures to Obtain Microscopically Negative Margins during Pancreaticoduodenectomy for Pancreatic Adenocarcinoma Is Worthwhile,” American Journal of Surgery, Vol. 75, No. 9, 2009, pp. 804-809.
 J. F. Helm, B. A. Centeno, D. Coppola, et al., “Outcomes Following Resection of Pancreatic Adenocarcinoma: 20-Year Experience at a Single Institution,” Cancer Control, Vol. 15, No. 4, 2008, pp. 288-294.
 P. Toomey, J. Hernandez, F. Golkar, et al., “Pancreatic Adenocarcinoma: Complete Tumor Extirpation Improves Survival Benefit despite Larger Tumors for Patients Who Undergo Distal Pancreatectomy and Splenectomy,” Journal of Gastrointestinal Surgery, Vol. 16, No. 2, 2012, pp. 376-381.
 G. R. Varadhachary, E. P. Tamm, J. L. Abbruzzese, et al., “Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy,” Annals of Surgical Oncology, Vol. 13, No. 8, 2006, pp. 1035-1046. http://dx.doi.org/10.1245/ASO.2006.08.011
 G. R. Varadhachary, E. P. Tamm, C. Crane, et al., “Borderline Resectable Pancreatic Cancer,” Current Treatment Options in Gastroenterology, Vol. 8, No. 5, 2005, pp. 377-384. http://dx.doi.org/10.1007/ s11938-005-0040-x
 M. H. Katz, P. W. Pisters, D. B. Evans, et al., “Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease,” Journal of the American College of Surgeons, Vol. 206, No. 5, 2008, pp. 833-846. http://dx.doi.org/10.1016/j.jamcollsurg.2007.12.020
 M. P. Callery, K. J. Chang, E. K. Fishman, et al., “Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement,” Annals of Surgical Oncology, Vol. 16, No. 7, 2009, pp. 1727-1733. http://dx.doi.org/10.1245/s10434-009-0408-6
 H. A. Burris III, M. J. Moore, J. Andersen, et al., “Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial,” Journal of Clinical Oncology, Vol. 15, No. 6, 1997, pp. 2403-2413.
 D. Tassinari, “Surrogate End Points of Quality of Life Assessment: Have We Really Found What We Are Looking for?” Health and Quality of Life Outcomes, Vol. 1, 2003, p. 71. http://dx.doi.org/10.1186/ 1477-7525-1-71
 A. Andriulli, V. Festa, E. Botteri, et al., “Neoadjuvant/ Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-Analysis of Prospective Studies,” Annals of Surgical Oncology, Vol. 19, No. 5, 2012, pp. 1644-1662. http://dx.doi.org/10.1245/s10434-011-2110-8
 D. Habermehl, K. Kessel, T. Welzel, et al., “Neoadjuvant Chemoradiation with Gemcitabine for Locally Advanced Pancreatic Cancer,” Radiation Oncology, Vol. 7, 2012, p. 28. http://dx.doi.org/10.1186/ 1748-717X-7-28
 S. Gillen, T. Schuster, C. Meyer Zum Buschenfelde, et al., “Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Response and Resection Percentages,” PLOS Medicine, Vol. 7, No. 4, 2010, Article ID: e1000267. http://dx.doi.org/10.1371/journal.pmed. 1000267
 C. J. Yeo, J. L. Cameron, K. D. Lillemoe, et al., “Pancreaticoduodenectomy for Cancer of the Head of the Pancreas. 201 Patients,” Annals of Surgery, Vol. 221, No. 6, 1995, pp. 721-731.
 P. Toomey, C. Childs, K. Luberice, S. Ross and A. Rosemurgy, “Nontherapeutic Celiotomy Incidence Is Not Affected by Volume of Pancreaticoduodenectomy for Pancreatic Adenocarcinoma,” American Journal of Surgery, Vol. 79, No. 8, 2013, pp. 781-785.
 L. Chang, D. Stefanidis, W. S. Richardson, et al., “The Role of Staging Laparoscopy for Intraabdominal Cancers: An Evidence-Based Review,” Surgical Endoscopy, Vol. 23, No. 2, 2009, pp. 231-241. http://dx.doi.org/10.1007/s00464-008-0099-2
 D. D. Von Hoff, R. K. Ramanathan, M. J. Borad, et al., “Gemcitabine plus Nab-Paclitaxel Is an Active Regimen in Patients with Advanced Pancreatic Cancer: A Phase I/II Trial,” Journal of Clinical Oncology, Vol. 29, No. 34, 2011, pp. 4548-4554. http://dx.doi.org/10.1200/JCO.2011.36.5742
 J. M. Pimiento, T. Hutchinson, J. M. Weber, M. R. Patel, P. J. Hodul, M. D. Chuong, G. M. Springett, S E. Hoffe, R. C. Karl, B. Centeno, J. Klapman, R. Shridhar, D. Chen and M. P. Malafa, “Multimodality Therapy for Borderline Resectable Pancreatic Cancer: A Single-Institution Experience,” Journal of Clinical Oncology, Vol. 30, Suppl. 4, 2012, Abstract 280.
 C. M. Kang, Y. E. Chung, J. Y. Park, et al., “Potential Contribution of Preoperative Neoadjuvant Concurrent Chemoradiation Therapy on Margin-Negative Resection in Borderline Resectable Pancreatic Cancer,” Journal of Gastrointestinal Surgery, Vol. 16, No. 3, 2012, pp. 509-517. http://dx.doi.org/10.1093/annonc/mds109
 J. M. Pipas, B. I. Zaki, M. M. McGowan, et al., “Neoadjuvant Cetuximab, Twice-Weekly Gemcitabine, and Intensity-Modulated Radiotherapy (IMRT) in Patients with Pancreatic Adenocarcinoma,” Annals of Oncology, Vol. 23, No. 11, 2012, pp. 2820-2827. http://dx.doi.org/10.1093/annonc/mds109
 N. D. Arvold, D. P. Ryan, A. Niemierko, et al., “LongTerm Outcomes of Neoadjuvant Chemotherapy before Chemoradiation for Locally Advanced Pancreatic Cancer,” Cancer, Vol. 118, No. 12, 2012, pp. 3026-3035.
 M. D. Chuong, T. J. Hayman, M. R. Patel, et al., “Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment after Neoadjuvant GTX-RT in BorderlineResectable Pancreatic Cancer,” Gastrointestinal Cancer Research, Vol. 4, No. 4, 2011, pp. 128-134.
 M. Patel, S. Hoffe, M. Malafa, et al., “Neoadjuvant GTX Chemotherapy and IMRT-Based Chemoradiation for Borderline Resectable Pancreatic Cancer,” Journal of Surgical Oncology, Vol. 104, No. 2, 2011, pp. 155-161. http://dx.doi.org/10.1002/jso.21954
 J. B. Stokes, N. J. Nolan, E. B. Stelow, et al., “Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer,” Annals of Surgical Oncology, Vol. 18, No. 3, 2011, pp. 619-627. http://dx.doi.org/10.1245/s10434-010-1456-7
 S. Takahashi, T. Kinoshita, M. Konishi, et al., “Borderline Resectable Pancreatic Cancer: Rationale for Multidisciplinary Treatment,” Journal of Hepato-Biliary-Pancreatic Sciences, Vol. 18, No. 4, 2011, pp. 567-574. http://dx.doi.org/10.1007/s00534-011-0371-z
 R. J. McClaine, A. M. Lowy, J. J. Sussman, et al., “Neoadjuvant Therapy May Lead to Successful Surgical Resection and Improved Survival in Patients with Borderline Resectable Pancreatic Cancer,” HPB (Oxford), Vol. 12, No. 1, 2010, pp. 73-79. http://dx.doi.org/10.1111/j.1477-2574.2009.00136.x
 M. Piperdi, T. P. McDade, J. K. Shim, et al., “A Neoadjuvant Strategy for Pancreatic Adenocarcinoma Increases the Likelihood of Receiving All Components of Care: Lessons from a Single-Institution Database,” HPB (Oxford), Vol. 12, No. 3, 2010, pp. 204-210.
 K. M. Brown, V. Siripurapu, M. Davidson, et al., “Chemoradiation Followed by Chemotherapy before Resection for Borderline Pancreatic Adenocarcinoma,” American Journal of Surgery, Vol. 195, No. 3, 2008, pp. 318-321. http://dx.doi.org/10.1016/j.amjsurg.2007.12.017
 J. L. Marti, H. S. Hochster, S. P. Hiotis, et al., “Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer,” Annals of Surgical Oncology, Vol. 15, No. 12, 2008, pp. 3521-3531. http://dx.doi.org/10.1245/s10434-008-0152-3
 W. Small Jr., J. Berlin, G. M. Freedman, et al., “Full-Dose Gemcitabine with Concurrent Radiation Therapy in Patients with Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial,” Journal of Clinical Oncology, Vol. 26, No. 6, 2008, pp. 942-947. http://dx.doi.org/10.1200/JCO.2007.13.9014
 P. Massucco, L. Capussotti, A. Magnino, et al., “Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival,” Annals of Surgical Oncology, Vol. 13, No. 9, 2006, pp. 1201-1208. http://dx.doi.org/10.1245/s10434-006-9032-x
 J. M. Pipas, R. J. Barth Jr., B. Zaki, et al., “Docetaxel/ Gemcitabine Followed by Gemcitabine and External Beam Radiotherapy in Patients with Pancreatic Adenocarcinoma,” Annals of Surgical Oncology, Vol. 12, No. 12, 2005, pp. 995-1004. http://dx.doi.org/10.1245/ASO.2005.04.503
 S. V. Shrikhande, S. Arya, S. G. Barreto, et al., “Borderline Resectable Pancreatic Tumors: Is There a Need for Further Refinement of This Stage?” Hepatobiliary & Pancreatic Diseases International, Vol. 10, No. 3, 2011, pp. 319-324. http://dx.doi.org/10.1016/S1499-3872(11)60053-2